Scholar Rock (NASDAQ:SRRK) is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.
The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA). In addition to its SMA candidate, Scholar Rock is advancing therapeutic candidates that inhibit other members of the transforming growth factor-beta (TGF-β) superfamily. These programs address indications such as fibrotic diseases, immuno-oncology and rare genetic bone disorders, with several assets in preclinical or early clinical development.
Scholar Rock’s proprietary platform combines structural biology, protein engineering and translational pharmacology to identify and optimize molecules that bind selectively to growth factor precursors or associated regulatory proteins. By focusing on the latency and activation mechanisms of signaling proteins, the company seeks to fine-tune growth factor activity, reduce off-target effects and expand the range of treatable conditions. Collaboration with academic institutions and strategic partnerships supports the advancement of its pipeline and fosters translational science.
Founded in 2013 and headquartered in Cambridge, Massachusetts, Scholar Rock is led by President and CEO Paul J. Rubin. The company conducts clinical trials and research collaborations in North America and engages with global regulators and investigators to advance its programs. Scholar Rock’s executive team and board include leaders with experience in biopharmaceutical development, clinical strategy and regulatory affairs, underscoring its commitment to delivering innovative therapies to patients with high-unmet-need conditions.
